Last update 24 Dec 2025
Shanghai Huilun Life Science & Technology Co. Ltd.

Shanghai Huilun Life Science & Technology Co. Ltd.

Private Company|2004|Shanghai Shi, China|
www.huilunbio.com

Overview

Tags

Neoplasms
Other Diseases
Respiratory Diseases
Small molecule drug
Chemical drugs

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms14
Infectious Diseases10
Nervous System Diseases9
Immune System Diseases8
Endocrinology and Metabolic Disease4
Top 5 Drug TypeCount
Small molecule drug24
Chemical drugs7
Top 5 TargetCount
IRAK4(Interleukin-1 receptor-associated kinase 4)2
ELA2(Leukocyte elastase)2
AR(Androgen Receptor)2
PSMB8 x PSMB91
PD-1(Programmed cell death protein 1)1

Related

31
Drugs associated with Shanghai Huilun Life Science & Technology Co. Ltd.
Relugolix
Target
GnRHR
Mechanism
GnRHR antagonists
Active Org.
Accord Healthcare SLU [+7]
Originator Org.
Takeda Pharmaceutical Co., Ltd.Takeda Pharmaceutical Co., Ltd.
Active Indication
Advanced Prostate Carcinoma [+10]
Inactive Indication
Dysmenorrhea [+3]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
Japan
First Approval Date08 Jan 2019
Levoleucovorin
Target-
Mechanism-
Active Org.
Pfizer Inc.Pfizer Inc. [+3]
Originator Org.
Spectrum Pharmaceuticals, Inc.Spectrum Pharmaceuticals, Inc.
Active Indication
Stomach Cancer [+6]
Inactive Indication
Pancreatic Cancer
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
Switzerland
First Approval Date16 Oct 2009
Sivelestat Sodium Hydrate
Target
ELA2
Mechanism
ELA2 inhibitors
Active Org.
Dong-A ST Co., Ltd.Dong-A ST Co., Ltd. [+3]
Originator Org.
Ono Pharmaceutical Co., Ltd.Ono Pharmaceutical Co., Ltd.
Active Indication
Acute Lung Injury [+1]
Inactive Indication
Community Acquired Pneumonia [+2]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
Japan
First Approval Date11 Apr 2002
64
Clinical Trials associated with Shanghai Huilun Life Science & Technology Co. Ltd.
CTR20254102
/ CompletedNot Applicable
雌二醇醋酸炔诺酮片单中心、随机、开放、两制剂、两序列、两周期交叉、空腹单次给药生物等效性试验
[Translation] A single-center, randomized, open-label, two-dose, two-sequence, two-period crossover, fasting single-dose bioequivalence study of estradiol and norethindrone acetate tablets
NCT07159243
/ Not yet recruitingPhase 2
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-designed Clinical Study to Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain
CTR20253202
/ RecruitingPhase 2
评价HL-1186片治疗糖尿病神经病理性疼痛有效性、安全性的多中心、随机、双盲、安慰剂平行对照II期临床研究
[Translation] A multicenter, randomized, double-blind, placebo-controlled phase II clinical study to evaluate the efficacy and safety of HL-1186 tablets in the treatment of diabetic neuropathic pain
100 Clinical Results associated with Shanghai Huilun Life Science & Technology Co. Ltd.
Login to view more data
0 Patents (Medical) associated with Shanghai Huilun Life Science & Technology Co. Ltd.
Login to view more data
100 Deals associated with Shanghai Huilun Life Science & Technology Co. Ltd.
Login to view more data
100 Translational Medicine associated with Shanghai Huilun Life Science & Technology Co. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 06 Jan 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
13
2
Preclinical
Phase 1
5
5
Phase 2
Phase 3
4
2
Approved
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
H062
Essential Hypertension
More
Phase 3
Dienogest
 ( ER x PR )		Adenomyosis
More
Phase 3
H077
Prostatic Hyperplasia
More
Phase 3
Relugolix
 ( GnRHR )		Uterine Fibroids
More
Phase 3
HTMC-0435
 ( PARP1 x PARP2 )		Advanced Malignant Solid Neoplasm
More
Phase 2
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free